Tango Therapeutics (NASDAQ:TNGX) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.35) by 2.86 percent. This is a 2.86 percent decrease over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $5.39 million which missed the analyst consensus estimate of $6.69 million by 19.45 percent. This is a 16.67 percent decrease over sales of $6.47 million the same period last year.